Cogent Biosciences, Inc. Operating Leases, Rent Expense
Cogent Biosciences, Inc. (COGT) reported Operating Leases, Rent Expense of $1.80 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-03-28
- Cogent Biosciences, Inc. operating leases, rent expense for the quarter ending 2018-12-31 was $500.00K, a 0.00% change year-over-year.
- Cogent Biosciences, Inc. operating leases, rent expense for the quarter ending 2018-09-30 was $400.00K, a 0.00% change year-over-year.
- Cogent Biosciences, Inc. operating leases, rent expense for the quarter ending 2018-06-30 was $400.00K, a 0.00% change year-over-year.
- Cogent Biosciences, Inc. operating leases, rent expense for the quarter ending 2018-03-31 was $400.00K, a 0.00% change year-over-year.
- Cogent Biosciences, Inc. operating leases, rent expense for fiscal 2018 was $1.80M, a 0.00% change from fiscal 2017.
- Cogent Biosciences, Inc. operating leases, rent expense for fiscal 2017 was $1.80M.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $900.00K derived: sum of 2 quarters · filed 2019-03-28 | $1.30M derived: sum of 3 quarters · filed 2019-03-28 | $1.80M 10-K · filed 2019-03-28 |
| 2018-09-30 | $400.00K 10-Q · filed 2018-11-13 | $800.00K derived: sum of 2 quarters · filed 2018-11-13 | $1.30M 10-Q · filed 2018-11-13 | $1.70M derived: sum of 4 quarters · filed 2019-03-28 |
| 2018-06-30 | $400.00K 10-Q · filed 2018-08-13 | $900.00K 10-Q · filed 2018-08-13 | $1.30M derived: sum of 3 quarters · filed 2019-03-28 | $1.70M derived: sum of 4 quarters · filed 2019-03-28 |
| 2018-03-31 | $400.00K 10-Q · filed 2018-05-14 | $900.00K derived: sum of 2 quarters · filed 2019-03-28 | $1.30M derived: sum of 3 quarters · filed 2019-03-28 | $1.70M derived: sum of 4 quarters · filed 2019-03-28 |
| 2017-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $900.00K derived: sum of 2 quarters · filed 2019-03-28 | $1.30M derived: sum of 3 quarters · filed 2019-03-28 | $1.80M 10-K · filed 2019-03-28 |
| 2017-09-30 | $400.00K 10-Q · filed 2018-11-13 | $800.00K derived: sum of 2 quarters · filed 2018-11-13 | $1.30M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $400.00K 10-Q · filed 2018-08-13 | $900.00K 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $400.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |